DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
UC and Broad have been involved in two interferences at the patent office. Interference No. 106,115 was the second interference between UC and Broad over patent rights to CRISPR-Cas9 technology in ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
A U.S. clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company runs global clinical ...
News-Medical.Net on MSN
ERC Proof of Concept grant supports promising CRISPR-based cancer treatment research
Microbiologist John van der Oost of Wageningen University & Research (WUR) has received an ERC Proof of Concept grant to further develop a promising CRISPR-based approach to cancer treatment. With ...
CHICAGO, IL—A novel in vivo gene-editing therapy based on CRISPR-Cas9 that targets inactivation of the transthyretin (TTR) gene could slow disease progression in patients with cardiomyopathy caused by ...
In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...
CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results